ImmunoCellular Therapeutics (OTCBB: IMUC) Licenses Mesothelin Cancer Antigen from Johns Hopkins University

Chicago, IL 3/1/12 (StreetBeat) – ImmunoCellular Therapeutics (OTCBB: IMUC) today announced that it has entered into an agreement with The Johns Hopkins University (JHU) under which JHU has granted the Company an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The terms of the agreement were not disclosed.

The Company will employ this intellectual property in the development and commercialization of ICT-140, a multivalent, dendritic cell-based vaccine for the treatment of ovarian cancer, one of multiple tumor types in which mesothelin is over-expressed. ICT-140 is designed to target cancer stem cells as well as daughter cells in ovarian cancer by targeting multiple different antigens including mesothelin, Her-2/neu, IL-13Rα2 and several other undisclosed antigens.

Manish Singh, Ph.D., IMUC’s president and CEO, commented, “As we continue the development of a novel, dendritic cell-based vaccine for the treatment of ovarian cancer, this licensing agreement for mesothelin technology will allow us to ensure that we have the critical components for a successful vaccine. We look forward to the ongoing support of Dr. Jaffee and her colleagues at Johns Hopkins as we develop the vaccine. We expect to file an Investigative New Drug application for the vaccine in the fourth quarter of this year.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com

StreetBeat Disclaimer

Distributed by Viestly

ImmunoCellular (OTCBB: IMUC) Shareholder Update Validates Strong Potential for Growth

Tallahassee, FL 2/10/12 (StreetBeat) – Biotechnology topics are hot in the investment community. Acquisitions are regularly being reported, new treatments are advancing in cancer therapy and stem cell research is being pursued down multiple avenues for its core competencies of repairing damaged body parts at the root of the problem. Bringing together these topics points to the direction of ImmunoCellular Therapeutics, Inc. (OTCBB:IMUC), a clinical stage biotechnology company targeting cancer stem cells by using the power of immunology and working in the same industry as Biogen Idec Inc. (NASDAQ:BIIB) and Amgen, Inc. (NASDAQ:AMGN). ImmunoCellular Therapeutics presents an investment opportunity that outstrips its much larger competitors as discernible from a recent letter to shareholders from IMUC President and CEO Manish Singh, Ph.D.

The company had a banner year in 2011 with a major milestone being hit with the initiation of a Phase II study for its flagship product candidate, ICT-107 (a dendritic cell-based vaccine). This Phase II study builds upon strong data collected in Phase I as an indication for glioblastoma, the most aggressive form of brain cancer. Phase I research showed ICT-107 outperforming current treatments by showing an 80% survival rate after two years compared to today’s rate of a mere 26.5% and a three-year survival rate of 55% as compared to 15% with standard care treatments. An amazing 38% of the patients treated with ICT-107 continue to show no signs of tumor recurrence after three years as opposed to the bleak rate of 6% in patients receiving standard care. No serious adverse events from the ICT-107 have been observed.

Moreover, ImmunoCellular has completed a $10.4 million financing, paving the way financially for the company through at least the end of 2013 for the ICT-107 Phase II trial and potentially the start of clinical trials for two more vaccines utilizing the same scientific principles as ICT-107 (ICT-140 for ovarian cancer and ICT-121 for recurrent glioblastoma). The financing leaves IMUC in an envious position with cash on hand in excess of $16 million, a strong balance sheet thanks to a lean infrastructure, a robust group of life science investors and absolutely no need for dilutive practices.

The Phase II study is more than halfway through enrollment with more than 115 patients enrolled out of the estimated 160-200 through initiation of the trial at 23 centers, including some of the most prestigious brain tumor treatment centers in the U.S. Enrollment is expected to be completed by the second quarter 2012.

The letter to shareholders covered the whole gamut of ImmunoCellular’s operations highlighting that the company is not only well-positioned for today, but is also forward-thinking and taking the necessary steps to secure its position as a leader in the immunotherapy sector. Amongst its many developments in the last year, IMUC has manufacturing agreements in place for ICT-107 formulations with Progenitor Cell Therapy, a subsidiary of NeoStem (AMEX:NBS); initiated a strategic collaboration and new Joint Venture (called Caerus Discovery) with BioWa to develop enhanced versions of IMUC antibodies; and expanded its patent portfolio.

Industry experts are recognizing the ingenuity of ICT-107 and giving it extensive praise, including it being hailed as one of the “100 Great Investigational Drugs” by R&D Directions, a “Top 10 Licensable Oncology Products” by Windhover, listed as a top ten therapeutic cancer vaccines by Fierce Biotech and being featured on CBS News as a “promising vaccine” for brain cancer.

ImmunoCellular has clearly established itself as a pioneer in immunotherapy and possesses the technology that could truly change the landscape of oncology. They are well-funded and organized, have an outstanding management team; they’re producing stellar clinical data and carry a price point that offers an upside which is arguably larger than any of its peers. All of these qualities align IMUC as a prime acquisition target in a field of merger-hunger major pharmas looking to take the lead in any given field. Keep an eye on this emerging micro-cap firm that could be shepherding in the next generation of brain cancer therapy right before our eyes. Interested parties are encouraged to read the letter to shareholders from Dr. Singh, and keep an alert out for the company’s next SEC filing.

ImmunoCellular to Present at the 14th Annual BIO CEO & Investor Conference

StreetBeat Disclaimer

Distributed by Viestly

ImmunoCellular Therapeutics (OTCBB: IMUC) Receives Notice of Allowance of Cancer Stem Cell Targeting Patent

Tallahassee, FL 2/2/12 (StreetBeat) -- ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company’s method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells (CSC). ImmunoCellular received notice from the U.S. Patent and Trademark Office that a patent titled “Cancer Stem Cell Antigen Vaccines and Methods,” which covers various methods of using dendritic cells combined with antigens derived from glioblastoma CSCs for the treatment of GBM has been allowed.

“The notice of allowance for this patent provides support for our strong intellectual property protection that we are building in the treatment of cancer by targeting cancer stem cells,” said John Yu, MD, ImmunoCellular’s Chairman of the Board and Chief Scientific Officer and a co-inventor of the technology covered by the patent that has been exclusively licensed to the Company. “We continue to actively develop our CSC platform as we believe it has significant potential in the treatment of cancer.”

ImmunoCellular Therapeutics is currently conducting a Phase-II double-blind, placebo-controlled, 2:1 randomized study designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. A separate patent covering a method of treating neural cancers using ICT-107 was recently issued by the U.S. Patent and Trademark Office on January 17, 2012.

StreetBeat Disclaimer

Distributed by Viestly

ImmunoCellular (OTC:IMUC) Raises $8.1M from PIPE

Summer Street Research Partners announced today the recent closing of a financing for ImmunoCellular Therapeutics (OTC:IMUC), a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular raised approximately $8.1 million primarily from U.S. based institutional investors. Summer Street Research Partners served as the lead placement agent for the transaction. As I write, shares of ImmunoCellular are down 4 percent at $2.15 per share on moderate volume of nearly 60,000 shares. The company has a market cap of $47 million and a 52-week range between $0.84 and $2.44 per share.

The Company recently started a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.

"Summer Street Research is very excited to be involved with ImmunoCellular, an innovative company with some of the most compelling data seen to date in Glioblastoma. We are delighted to assist them with this financing and the interest from high quality fundamental healthcare investors," said Al Sollami, CEO of Summer Street Research Partners.

Summer Street Research Partners is an investment banking, institutional equity research and trading firm that focuses exclusively on the healthcare sector.

For more information on Summer Street Research Partners, please visit its Web site: www.ssrp.com.

For more information on ImmunoCellular, please visit its Web site: www.imuc.com.

Distributed by IntelBuilder Social Media Platform